Lumicell
Lumicell illuminates cancer and other diseased tissues at the molecular level, enabling physicians to take action in real-time during surgeries to improve patient outcomes.
Insight Through Illumination
Currently in use across the United States, Lumicell is investigating the use of its therapy in patients undergoing surgery for breast cancer, ovarian cancer, prostate cancer, brain cancer, colorectal, esophageal and pancreatic cancers.
Lumicell illuminates cancer and other diseased tissues at the molecular level, enabling physicians to take action in real-time during surgeries to improve patient outcomes.
The company’s lead product, the Lumicell System, is in late-stage development for breast cancer surgery. It features an investigational onco-fluorescent agent and a handheld imaging device that enable cancer surgeons to see and remove cancer cells in real-time during operations. The Lumicell System was designed and developed by MIT engineers in partnership with leading breast cancer surgeons to fit seamlessly within the existing surgical workflow. Lumicell is investigating the use of its therapy in patients undergoing surgery for breast cancer, ovarian cancer, prostate cancer, brain cancer, colorectal, esophageal and pancreatic cancers.
In the News
Lumicell Announces U.S. Launch and First Commercial Use of LumiSystem™
Lumicell has announced the commercial launch of LumiSystem™, the first FDA-approved fluorescence-guided imaging technology for breast cancer that enables real-time detection and removal of residual cancer during lumpectomy, helping improve surgical outcomes and reduce the need for second surgeries.
Read More
Starting October 1, 2024, Medicare will reimburse for LUMISIGHT™ under a new pass-through payment, expanding access to Lumicell’s FDA-approved imaging agent that helps detect residual breast cancer during surgery.
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer
The FDA has approved Lumicell’s LumiSystem—combining LUMISIGHT™ and Lumicell™ DVS—which enables real-time, fluorescence-guided detection of residual breast cancer during lumpectomy with 84% diagnostic accuracy, helping reduce the need for second surgeries and marking a major advancement in intraoperative cancer care.